Title : Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.

Pub. Date : 2012

PMID : 22701615






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 METHODS: Vandetanib (an orally bioavailable VEGFR-2 and EGFR tyrosine kinases inhibitor) was combined at 100 mg, 200 mg, or 300 mg daily with standard dosed cetuximab and irinotecan (3+3 dose-escalation design). vandetanib kinase insert domain receptor Homo sapiens